series-b
Stage
1
Investors
About
NovalGen is a clinical-stage biotechnology company developing multi-specific biologic immunotherapies. The company is advancing an AutoRegulation platform to create self-regulating antibody and T-cell engager therapies for oncology, autoimmune, haematological, and metabolic disorders.
Explore NovalGen's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.